Small. Light. Designed for everyday life.
Optune is small and light, weighing just 2.7 pounds. This makes Optune wearable and portable, so continuous treatment with Optune can be received almost anywhere.
Electric field generator
The portable field generator should be carried with you to deliver Tumor Treating Fields (TTFields) as you go about your day.
Connection cable and box
Black and white color-coded sockets on the cable box help ensure that transducer array connectors are properly connected.
Messenger bag
Openings conveniently located at the top and bottom make it easy to reach device controls.
Available in a convertible backpack
The convertible backpack can be worn 5 different ways and has additional battery storage, making it ideal for on-the-go use.
Transducer arrays
Four sterile, single-use transducer arrays are connected to the electric field generator to deliver therapy. Transducer arrays should be changed at least 2 times per week (one set of arrays should not be worn for more than 4 days at a time).
Portable batteries and charger
A handy charger keeps portable batteries charged and ready to fit your schedule.
Portable battery
A portable battery gives you on-the-go convenience.
Wall power supply
This plug-in power supply lets you keep your device on without interrupting therapy while you change the battery.
The system offers features designed to enhance carrying comfort and usability:
Other components include:
Applying transducer arrays
Optune delivers therapy through 4 adhesive patches, called transducer arrays. These arrays are applied to your scalp. They are powered through the connection cable and box, which is powered by the battery. If you are starting treatment with Optune, applying transducer arrays will soon become a part of your routine. With the help of a caregiver, your head will be shaved and arrays changed at least 2 times per week. Do not wear the same set of arrays for more than 4 days at a time.
You can cover transducer arrays with breathable head coverings
For more suggestions from Optune users, see the suggestions on the next page.
MyLink™—designed to be an easier way to upload Optune usage data
Optune records the amount of time that therapy is delivered per day. Your MyLink unit pairs with your Optune device to securely transfer your usage data.
MyLink enables you to upload your electric field generator data from the comfort of your home. This means Novocure® can collect data more frequently to better support you.
Your Device Support Specialist (DSS) can view your secure data remotely. Then your DSS can inform you about your device usage.
Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.
If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:
If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:
Optune Lua is a wearable, portable, FDA-approved device indicated for the treatment of adult patients, with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used together with standard chemotherapy (pemetrexed and platinum-based chemotherapy).
Optune for GBM and Optune Lua for MPM are not for everyone. Talk to your doctor if you have:
Do not use Optune for GBM or Optune Lua for MPM if you are pregnant or are planning to become pregnant. It is not known if Optune/Optune Lua is safe or effective during pregnancy.
Optune and Optune Lua should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune and Optune Lua.
The most common side effects of Optune when used together with chemotherapy for GBM (temozolomide or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, seizure, and depression.
The most common side effects when using Optune alone for GBM were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.
The most common side effects of Optune Lua when used together with chemotherapy for MPM (pemetrexed and platinum-based chemotherapy) were low red blood cell count, constipation, nausea, tiredness, chest pain, fatigue, skin irritation from device use, itchy skin, and cough.
Other potential adverse effects associated with the use of Optune Lua include: treatment related skin irritation, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.
Talk to your doctor if you have any of these side effects or questions.
Caution: Federal law restricts Optune Lua to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.
Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.
Please click here to see the Optune Lua IFU for complete information regarding the device's indications, contraindications, warnings, and precautions.
On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals. Patient images reflect the health status of the patients at the time each photo was taken.
Optune is indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.
Hover over to explore the Optune system